ICM
OMCL icon

Invenomic Capital Management’s Omnicell OMCL Stock Holding History

Invenomic Capital Management’s Portfolio OMCL Stock Details OMCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-268,695
Closed -$7.27M – 172
2024
Q2 		$7.27M Buy
268,695
+85,580
+47% +$2.48M 0.35% 82
2024
Q1 		$5.35M Buy
183,115
+78,512
+75% +$2.38M 0.28% 91
2023
Q4 		$3.94M Buy
+104,603
New +$3.85M 0.18% 120

Other funds holding OMCL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invenomic Capital Management's OMCL Position: Q3 2024 in Review

Invenomic Capital Management sold out of Omnicell (OMCL) in Q3 2024, closing a stake of 268,695 shares — an estimated $7.27M sold.

Invenomic Capital Management first reported a position in OMCL in Q4 2023 and held it in 3 quarters. The position peaked at $7.27M in Q2 2024. 259 funds tracked by Wall St. Rank hold OMCL as of Q3 2024.

  • Invenomic Capital Management reported no remaining Omnicell position as of Q3 2024 after selling out during the quarter.
  • Invenomic Capital Management sold 268,695 Omnicell shares in Q3 2024, an estimated $7.27M.
  • Invenomic Capital Management first reported a position in Omnicell in Q4 2023 and held it in 3 quarters.
  • Invenomic Capital Management's Omnicell position peaked at $7.27M in Q2 2024.
  • 259 funds tracked by Wall St. Rank held Omnicell as of Q3 2024.

Based on Invenomic Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.